WO2020130838A3 - Anticorps pour la prévention ou le traitement de la candidose - Google Patents

Anticorps pour la prévention ou le traitement de la candidose Download PDF

Info

Publication number
WO2020130838A3
WO2020130838A3 PCT/NL2019/050875 NL2019050875W WO2020130838A3 WO 2020130838 A3 WO2020130838 A3 WO 2020130838A3 NL 2019050875 W NL2019050875 W NL 2019050875W WO 2020130838 A3 WO2020130838 A3 WO 2020130838A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
vhh
further relates
invention further
albicans
Prior art date
Application number
PCT/NL2019/050875
Other languages
English (en)
Other versions
WO2020130838A2 (fr
Inventor
Cornelus Theodorus VERRIPS
Edward Dolk
Frank Martin SAUER
Bernhard HUBE
Selene MOGAVERO
Original Assignee
Qvq Holding B.V.
Leibniz Institute For Natural Product Research And Infection Biology, Hans Knoell Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qvq Holding B.V., Leibniz Institute For Natural Product Research And Infection Biology, Hans Knoell Institute filed Critical Qvq Holding B.V.
Publication of WO2020130838A2 publication Critical patent/WO2020130838A2/fr
Publication of WO2020130838A3 publication Critical patent/WO2020130838A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un anticorps à domaine variable à chaîne lourde unique (VHH) qui se lie à Ece1p, et/ou un peptide dérivé de celui-ci, à partir de C. albicans. L'invention concerne en outre un VHH qui reconnaît les protéines de paroi cellulaire de C. albicans hyphae, telles que Als3p. L'invention concerne en outre un anticorps bi- ou multi-spécifique comprenant un tel VHH et un anticorps mono- ou bispécifique comprenant un tel VHH fusionné sur un niveau de gène à la partie Fc d'anticorps humains et des méthodes et des moyens de production de tels VHH. L'invention concerne en outre un anticorps de l'invention, destiné à être utilisé dans des applications diagnostiques et destiné à être utilisé en tant que médicament. L'invention concerne en outre des anticorps à domaine variable à chaîne lourde unique qui se lient aux adhésines de C. albicans et des champignons pathogènes associés. L'invention concerne en outre un anticorps de l'invention, destiné à être utilisé dans des applications diagnostiques ou destiné à être utilisé en tant que médicament. L'invention concerne en outre un microbicide comprenant un anticorps de l'invention, et une composition pharmaceutique comprenant un anticorps de l'invention. L'invention concerne enfin des bactéries lactiques de qualité alimentaire qui expriment un VHH contre Ece1p ou des adhésines.
PCT/NL2019/050875 2018-12-21 2019-12-23 Anticorps pour la prévention ou le traitement de la candidose WO2020130838A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2022281 2018-12-21
NL2022281 2018-12-21

Publications (2)

Publication Number Publication Date
WO2020130838A2 WO2020130838A2 (fr) 2020-06-25
WO2020130838A3 true WO2020130838A3 (fr) 2020-07-30

Family

ID=65576597

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2019/050875 WO2020130838A2 (fr) 2018-12-21 2019-12-23 Anticorps pour la prévention ou le traitement de la candidose

Country Status (1)

Country Link
WO (1) WO2020130838A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023039577A1 (fr) * 2021-09-10 2023-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Nanocorps à neutralisation large contre le coronavirus et leurs utilisations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097689A2 (fr) * 2005-03-18 2006-09-21 Domantis Limited Anticorps
WO2007072022A2 (fr) * 2005-12-22 2007-06-28 Domantis Limited Composition
WO2014141094A1 (fr) * 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Conjugué anticancéreux
WO2014167335A1 (fr) * 2013-04-11 2014-10-16 King's College London Peptides et partenaires de liaison associés

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
AU3295299A (en) 1998-02-19 1999-09-06 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
WO2006040153A2 (fr) 2004-10-13 2006-04-20 Ablynx N.V. Nanocorps™ contre la proteine beta-amyloide et polypeptides les renfermant pour le traitement de maladies degeneratives neurales, telles que la maladie d'alzheimer
MX2007014564A (es) 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097689A2 (fr) * 2005-03-18 2006-09-21 Domantis Limited Anticorps
WO2007072022A2 (fr) * 2005-12-22 2007-06-28 Domantis Limited Composition
WO2014141094A1 (fr) * 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Conjugué anticancéreux
WO2014167335A1 (fr) * 2013-04-11 2014-10-16 King's College London Peptides et partenaires de liaison associés

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE BERNARDIS FLAVIA ET AL: "Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis", JOURNAL OF INFECTIOUS DISEASES. JID, UNIVERSITY OF CHICAGO PRESS, US, vol. 195, no. 1, 1 January 2007 (2007-01-01), pages 149 - 157, XP002470366, ISSN: 0022-1899, DOI: 10.1086/509891 *
SARAH HÖFS: "Identification of Candidalysin a Candida albicanspeptide toxin involved in epithelial damage - DISSERTATION", 25 August 2016 (2016-08-25), XP002792698, Retrieved from the Internet <URL:https://pdfs.semanticscholar.org/5d58/b5a7bf527762866197a4a7bac09cac4c4bae.pdf> [retrieved on 20190705] *

Also Published As

Publication number Publication date
WO2020130838A2 (fr) 2020-06-25

Similar Documents

Publication Publication Date Title
PH12019500545A1 (en) Cd3 binding antibodies
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
MX2018016404A (es) Anticuerpos de union a cd3.
MX2019013142A (es) Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion.
WO2018075857A8 (fr) Nouveaux anticorps monoclonaux anti-cd 47 et leurs utilisations
WO2016033225A3 (fr) Anticorps, compositions et leurs utilisations
MX2020006715A (es) Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
WO2018017864A3 (fr) Agents de liaison à pvrig et leurs utilisations
MX2022010487A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
EA201792221A1 (ru) Антитела против сортилина и способы их применения
MY189836A (en) Antibodies against cd73 and uses thereof
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
PE20190737A1 (es) Anticuerpos anti-cd27
MX344971B (es) Anticuerpos anti-ctla4 humanizados.
WO2014144763A3 (fr) Anticorps anti-gd2 à haute affinité
SG10201807877TA (en) Hybrid immunoglobulin containing non-peptidyl linkage
WO2019234241A8 (fr) Anticorps anti-oxmif/anti-cd3 pour le traitement de cancers
WO2018183182A8 (fr) Procédés et compositions pour la réduction d&#39;immunogénicité
WO2018115017A3 (fr) Structure cristalline de gremlin-1 et anticorps inhibiteur
WO2018194496A3 (fr) Anticorps monoclonal à pd-l1
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
WO2011092593A3 (fr) Anticorps neutralisant le vih-1 et leurs utilisations
WO2020065330A3 (fr) Récepteur antigénique chimérique
MX2021005085A (es) Formulacion de anticuerpo.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19835549

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19835549

Country of ref document: EP

Kind code of ref document: A2